#None #Sinovac Biotech #Heng Ren Investments #CoronaVac

Independent Shareholders of Sinovac Demand Immediate Dividend Payment

Independent shareholders of Sinovac Biotech Ltd., represented by Heng Ren Silk Road Investments LLC, are calling for the immediate disbursal of a $19.00 dividend declared by the board earlier this year. With more than 100 shareholders voicing their strong support, this demand underscores a growing frustration with the prolonged inaction from Sinovac's management amid a significant trading halt.

Since 2019, trading of Sinovac’s stocks has been completely suspended, which has left shareholders unable to capitalize on the extraordinary success of its COVID-19 vaccine, CoronaVac. As a result, these investors missed out on the financial windfall generated by billions in sales during the pandemic. Earlier this year, in July, the current board sought to assuage some of this frustration by issuing a one-time $55.00 dividend.

However, this was merely a partial remedy, as many shareholders remain dissatisfied with the lack of communication surrounding additional dividends. The board officially declared a further $19.00 dividend per common share on June 17, 2025, in an attempt to repay dividends that had not been issued to independent shareholders during the trading freeze. Alarmingly, it has now been more than four months since this announcement, yet no dates have been provided for the record and payment of said dividends.

This delay is particularly surprising considering that the current board and a consortium led by SAIF, aimed at replacing said board, both pledged to prioritize dividends for the benefit of shareholders during their campaigns. Peter Halesworth, founder of Heng Ren and a vocal advocate for shareholder rights, stated, "All parties involved—from the board to management—must recognize and respect the transparent desires of independent shareholders. Our support for immediate dividend distribution is overwhelmingly clear. It is time for the board to set a record and payment date for the promised dividend without further delay."

For more details about the “Sinovac Fairness” campaign spearheaded by Heng Ren, interested parties can visit Heng Ren Investments. This week, Heng Ren will host a webinar inviting shareholders to discuss the ongoing voting process and address any issues that voters face. Participants are encouraged to review their voting materials and come prepared with questions.

The situation at Sinovac serves as a critical reminder of the need for companies to maintain open lines of communication with their shareholders, especially when significant financial decisions are at stake. As many investors hold their breath waiting for a resolution, it remains to be seen how the board and management will respond to the mounting pressure from independent stakeholders, or whether they will make the necessary adjustments to meet shareholder expectations in a timely manner.